Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study

Morozova, M.A.; Lepilkina, T.A.; Rupchev, G.E.; Beniashvily, A.G.; Burminskiy, D.S.; Potanin, S.S.; EvgenyV, B.; Kazey, V.I.; Yan, L.; AlexandreV, I.

Авторы: Morozova Margarita A., Lepilkina Taisiya A., Rupchev Georgy E., Beniashvily Allan G., Burminskiy Denis S., Potanin Sergey S., EvgenyV Bondarenko, Kazey Vasily I., Yan Lavrovsky, and AlexandreV Ivachtchenko
Журнал: ORIGINAL RESEARCH CNS Spectrums. Cambridge University Press
Номер: №19(4)
Год издания: 2014
Первая страница: 316
Последняя страница: 323
DOI: 10.1017/S1092852913000394
Аннотация: The serotoninergic system as a target for add-on treatment seems to be a promising approach in patients with schizophrenia. Objective To clarify if selective 5HT-6 antagonist AVN-211 (CD-008-0173) adds clinical and cognitive effects to stable antipsychotic treatment. Methods A randomized, double-blind, placebo-controlled, add-on, 4r-week trial in 47 schizophrenia patients (21 patients receiving study drug and 26 receiving placebo) who were stabilized on antipsychotic medication was performed. Seventeen patients from the study drug group and 25 patients from the placebo group completed the trial. Treatment effects were measured using clinical rating scales and attention tests. Results With no differences at baseline, there was a significant difference between the groups in Positive and Negative Syndrome Scale (PANSS) positive subscale score (p = 0.058) in favor of patients in the treatment group at the endpoint. The PANSS positive subscore (p = 0.0068) and Clinical Global Impression–Severity (CGI-S) (p = 0.048) score significantly changed only in the treatment group. Only in the placebo group were significant changes in Calgary Depression Rating Scale (CDRS) total score registered. The indices of attention tests at endpoint did not show differences between the groups, with the exception of the scope of change in the results of the subtest VIII of the Wechsler Adult Intelligence Scale (WAIS), which showed difference between the groups (p = 0.02) and was significantly larger in the treatment group. Only inside the study drug group, significant changes in selectivity and continuous attention were observed regarding total correct responses (p = 0.0038) and reaction time (p = 0.058) in the Continuous Attention Task (CAT) test. Conclusion Selective 5HT6 antagonist AVN-211 (CD-008-0173) added antipsychotic and some procognitive (attention) effects to antipsychotic medication. (Received April 11 2013) (Accepted May 01 2013) (Online publication June 17 2013) Key words 5HT6 receptor antagonist; add-on; clinical effects; schizophrenia
Добавил в систему: Рупчев Георгий Евгеньевич

	ИСТИНА	Войти в систему Регистрация
	ФНКЦ РР
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ФНКЦ РР

Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot studyстатья

Прикрепленные файлы